General
Preferred name
EDOXABAN
Synonyms
EDOXABAN TOSYLATE HYDRATE ()
DU-176b tosylate Monohydrate ()
DU-176b monohydrate ()
Lixiana ()
Edoxaban (tosylate monohydrate) ()
EDOXABAN TOSYLATE ()
DU-176b ()
Edoxaban tosilate ()
Edoxaban (tosylate) ()
DU-176 ()
DU-176b (monohydrate) ()
DU-176b, Savaysa ()
Edoxaban Tosylate Monohydrate ()
Roteas ()
Savaysa ()
Edoxaban-d6 ()
P&D ID
PD009142
CAS
912273-65-5
1229194-11-9
480449-70-5
480449-71-6
1304701-57-2
Tags
available
drug
Approved by
FDA
PMDA
EMA
First approval
2011
2015
Drug indication
Atrial fibrillation
Venous thromboembolism
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research[1].
PRICE 69
INDICATION Edoxaban is indicated for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.
DESCRIPTION Edoxaban is an oral, once-daily factor Xa inhibitor anticoagulant.
Marketed formulations contain edoxaban tosylate (PubChem CID 44610678). (GtoPdb)
DESCRIPTION Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research[1].
PRICE 64
DESCRIPTION Edoxaban (Lixiana) (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K i s of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and is able to be used for stroke prevention. Edoxaban is a also weak inhibitor of thrombin and factor IXa?? (FIXa), with K i s of 6.00 ??M and 41.7 ??M, respectively, exhibits >10 000-fold selectivity for FXa. Edoxaban has antithrombotic properties and is potential for thromboembolic diseases treatment [1] [2] [3].
DESCRIPTION Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research[1].
DESCRIPTION Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention. (TargetMol Bioactive Compound Library)
DESCRIPTION Edoxaban is an anticoagulant used for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). It is a rapidly acting, oral, selective factor Xa inhibitor. (Enamine Bioactive Compounds)
DESCRIPTION Edoxaban (Lixiana) (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K i s of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and is able to be used for stroke prevention. Edoxaban is a also weak inhibitor of thrombin and factor IXaβ (FIXa), with K i s of 6.00 μM and 41.7 μM, respectively, exhibits >10 000-fold selectivity for FXa. Edoxaban has antithrombotic properties and is potential for thromboembolic diseases treatment [1] [2] [3]. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
0
Compound Sets
25
AdooQ Bioactive Compound Library
A14317
A18015
Axon Medchem Screening Library
3116
Cayman Chemical Bioactives
24030
25760
ChEMBL Approved Drugs
CHEMBL1269025
CHEMBL2105682
ChEMBL Drugs
CHEMBL1269025
CHEMBL2105682
Concise Guide to Pharmacology 2017/18
7575
Concise Guide to Pharmacology 2019/20
7575
Concise Guide to Pharmacology 2021/22
7575
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB09075
DrugBank Approved Drugs
DB09075
DrugCentral
4897
DrugCentral Approved Drugs
4897
DrugMAP
DMCIJBH
DrugMAP Approved Drugs
DMCIJBH
Enamine Bioactive Compounds
EBC-27305
EU-OPENSCREEN Bioactive Compound Library
EOS101162
Guide to Pharmacology
7575
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1269025
MedChem Express Bioactive Compound Library
HY-10264B
HY-10264
HY-10264A
NCATS Inxight Approved Drugs
NDU3J18APO
ReFrame library
Selleckchem Bioactive Compound Library
edoxaban
edoxaban-du-176b
TargetMol Bioactive Compound Library
T2368
T2368L
External IDs
71
Properties
(calculated by RDKit )
Molecular Weight
547.18
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
2
cLogP
1.29
TPSA
136.63
Fraction CSP3
0.5
Chiral centers
3.0
Largest ring
6.0
QED
0.48
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Factor Xa
Thrombin
F10
Factor Xa inhibitor
Disease Area
neurology/psychiatry, hematology, cardiology
Indication
stroke, pulmonary embolism (PE), systemic embolism, deep vein thrombosis (DVT), atrial fibrillation (AF)
MOA
coagulation factor inhibitor
Pathway
Metabolic Enzyme/Protease
Metabolism
Proteases/Proteasome
Source data